Timothy Rolph
Chief Scientific Officer · Akero Therapeutics, Inc.
- 2024
- Dec 9, 2025
- 12
Other insiders active in the same stocks
Insiders who have reported open-market trades at the same companies as Timothy Rolph. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Andrew Cheng - $13.35M in AKRO purchases and sales on record
- Jonathan Young - $5.28M in AKRO purchases and sales on record
- Catriona Yale - $2.80M in AKRO purchases and sales on record
- Patrick Lamy - $163K in AKRO purchases and sales on record
- Jane Henderson - $142K in AKRO purchases and sales on record
- William Richard White - $115K in AKRO purchases and sales on record
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Timothy Rolph?
Timothy Rolph is a corporate insider, tracked as Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO). InsiderAlpha holds 12 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Timothy Rolph last file a Form 4?
The most recent primary Form 4 on record is dated 9 December 2025, one of 12 filings going back to 2024.
Has Timothy Rolph been buying or selling stock?
Recorded transactions: 0 open-market purchases and 13 open-market sales ($2.67M) across all tracked filings.
